Early therapy for HIV vital

February 1, 2013

New insight into the optimal timing of therapy for HIV infection could give patients a better chance of responding to potential cure strategies of the future.

A new study has found antiretroviral administered within four months of restores the immune system back to healthy levels. Patients demonstrated stronger and faster recovery of the body's CD4+ T-cells than patients who started therapy later.  CD4+ T-cells are specialised required to fight infections and are depleted during HIV infection.

Published in The , the study, co-authored by Monash University's Associate Professor Edwina Wright with physicians from The University of Texas and the University of California, drew data of 468 patients followed over a 48-month period in the San Diego Primary Infection Cohort.

The study also found that patients with higher counts of CD4+ T-cells at the initiation of therapy demonstrated a stronger recovery of CD4+ T-cell counts than patients who start therapy later.

Associate Professor Wright said further clinical studies were needed to determine whether starting antiretroviral therapy earlier could enhance the chance of responding to future cure strategies.

"In the four months after HIV infection the immune system mounts an and starts to recover naturally before it subsequently progressively declines. This observation tells us that there may be a narrow restorative window that could be targeted for recovery through earlier initiation of potent antiretroviral therapy," Associate Professor Wright said.

"Through early therapy, full recovery of the CD4+ T-cell count could make a critical difference to the immune system's overall health and the individuals capacity to directly fight off infections, tumours and disease. This knowledge may also better position them to be successful if any HIV curatives come along."

Associate Professor Wright said even a short deferral of antiretroviral therapy outside of the four-month window could compromise CD4+ T-cell recovery, irrespective of the CD4+ count at the time of treatment initiation.

Associate Professor Wright and colleagues at Monash University are also involved in a major new clinical trial, the START study, designed to look at the benefits of immediate versus deferred antiretroviral treatment in people with HIV infection.

The trial is being conducted in 30 countries and will recruit 4000 HIV-infected men and women. Participants will be followed for up to five years.

More information: www.nejm.org/doi/full/10.1056/NEJMoa1110187

Related Stories

New memory for HIV patients

March 26, 2012

The hallmark loss of helper CD4+ T cells during human immunodeficiency virus (HIV) infection may be a red herring for therapeutics, according to a study published on March 26th in the Journal of Experimental Medicine.

Recommended for you

Potential new HIV therapy seen in immune cells

June 29, 2015

A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The study, published ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.